Cargando…

A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial

INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal c...

Descripción completa

Detalles Bibliográficos
Autores principales: March, Daniel S., Hurt, Adam W., Grantham, Charlotte E., Churchward, Darren R., Young, Hannah M.L., Highton, Patrick J., Dungey, Maurice, Bishop, Nicolette C., Smith, Alice C., Graham-Brown, Matthew P.M., Cooper, Nicola J., Burton, James O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207470/
https://www.ncbi.nlm.nih.gov/pubmed/34169195
http://dx.doi.org/10.1016/j.ekir.2021.02.036
_version_ 1783708783627730944
author March, Daniel S.
Hurt, Adam W.
Grantham, Charlotte E.
Churchward, Darren R.
Young, Hannah M.L.
Highton, Patrick J.
Dungey, Maurice
Bishop, Nicolette C.
Smith, Alice C.
Graham-Brown, Matthew P.M.
Cooper, Nicola J.
Burton, James O.
author_facet March, Daniel S.
Hurt, Adam W.
Grantham, Charlotte E.
Churchward, Darren R.
Young, Hannah M.L.
Highton, Patrick J.
Dungey, Maurice
Bishop, Nicolette C.
Smith, Alice C.
Graham-Brown, Matthew P.M.
Cooper, Nicola J.
Burton, James O.
author_sort March, Daniel S.
collection PubMed
description INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal cost-effectiveness analysis of adult participants with end-stage kidney disease undertaking in-center maintenance hemodialysis enrolled in the CYCLE-HD trial. Data on hospital utilization, primary care consultations, and prescribed medications were extracted from medical records for the 6 months before, during, and after a 6-month program of thrice-weekly IDC. The cost-effectiveness analysis was conducted from a health care service perspective and included the cost of implementing the IDC intervention. The base-case analyses included a 6-month “within trial” analysis and a 12-month “within and posttrial” analysis considering health care utilization and quality of life (QoL) outcomes. RESULTS: Data from the base-case within trial analysis, based on 109 participants (n = 56 control subjects and n = 53 IDC subjects) showed a reduction in health care utilization costs between groups, favoring the IDC group, and a 73% chance of IDC being cost-effective compared with control subjects at a willingness to pay of £20,000 and £30,000 per quality-adjusted life year (QALY) gained. When QoL data points were extrapolated forward to 12 months, the probability of IDC being cost-effective was 93% and 94% at £20,000 and £30,000 per QALY gained. Sensitivity analysis broadly confirms these findings. CONCLUSION: A 6-month program of IDC is cost-effective and the implementation of these programs nationally should be a priority.
format Online
Article
Text
id pubmed-8207470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82074702021-06-23 A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial March, Daniel S. Hurt, Adam W. Grantham, Charlotte E. Churchward, Darren R. Young, Hannah M.L. Highton, Patrick J. Dungey, Maurice Bishop, Nicolette C. Smith, Alice C. Graham-Brown, Matthew P.M. Cooper, Nicola J. Burton, James O. Kidney Int Rep Clinical Research INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal cost-effectiveness analysis of adult participants with end-stage kidney disease undertaking in-center maintenance hemodialysis enrolled in the CYCLE-HD trial. Data on hospital utilization, primary care consultations, and prescribed medications were extracted from medical records for the 6 months before, during, and after a 6-month program of thrice-weekly IDC. The cost-effectiveness analysis was conducted from a health care service perspective and included the cost of implementing the IDC intervention. The base-case analyses included a 6-month “within trial” analysis and a 12-month “within and posttrial” analysis considering health care utilization and quality of life (QoL) outcomes. RESULTS: Data from the base-case within trial analysis, based on 109 participants (n = 56 control subjects and n = 53 IDC subjects) showed a reduction in health care utilization costs between groups, favoring the IDC group, and a 73% chance of IDC being cost-effective compared with control subjects at a willingness to pay of £20,000 and £30,000 per quality-adjusted life year (QALY) gained. When QoL data points were extrapolated forward to 12 months, the probability of IDC being cost-effective was 93% and 94% at £20,000 and £30,000 per QALY gained. Sensitivity analysis broadly confirms these findings. CONCLUSION: A 6-month program of IDC is cost-effective and the implementation of these programs nationally should be a priority. Elsevier 2021-04-08 /pmc/articles/PMC8207470/ /pubmed/34169195 http://dx.doi.org/10.1016/j.ekir.2021.02.036 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
March, Daniel S.
Hurt, Adam W.
Grantham, Charlotte E.
Churchward, Darren R.
Young, Hannah M.L.
Highton, Patrick J.
Dungey, Maurice
Bishop, Nicolette C.
Smith, Alice C.
Graham-Brown, Matthew P.M.
Cooper, Nicola J.
Burton, James O.
A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
title A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
title_full A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
title_fullStr A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
title_full_unstemmed A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
title_short A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial
title_sort cost-effective analysis of the cycle-hd randomized controlled trial
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207470/
https://www.ncbi.nlm.nih.gov/pubmed/34169195
http://dx.doi.org/10.1016/j.ekir.2021.02.036
work_keys_str_mv AT marchdaniels acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT hurtadamw acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT granthamcharlottee acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT churchwarddarrenr acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT younghannahml acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT hightonpatrickj acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT dungeymaurice acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT bishopnicolettec acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT smithalicec acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT grahambrownmatthewpm acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT coopernicolaj acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT burtonjameso acosteffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT marchdaniels costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT hurtadamw costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT granthamcharlottee costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT churchwarddarrenr costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT younghannahml costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT hightonpatrickj costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT dungeymaurice costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT bishopnicolettec costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT smithalicec costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT grahambrownmatthewpm costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT coopernicolaj costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial
AT burtonjameso costeffectiveanalysisofthecyclehdrandomizedcontrolledtrial